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The pharmacokinetics, biological effects and distribu-
tion in blood and organs of 
125I-labeled (1®®®®® 3)-bbbbb -D-glucan
purified from  Candida albicans were analyzed in rab-
bits during the  24-h period following  an intravenous
adm inistration. The intravascular half-life of (1®®®®® 3)-bbbbb -
D-glucan w as 1.8 m in in the low-dose group (9.3 mmmmm g/kg)
and 1.4 m in in the high-dose group (222 mmmmm g/kg), and the
m ean (‰ SD) total body clearance was 1.12 ‰0.30 and
1.17 ‰0.16 m l/m in, respectively. The rabbits rem ained
well  and  (1®®®®® 3)-bbbbb -D-glucan  failed  to  alter  blood  cell
counts. Less than 3%  of the 
125I-(1®®®®® 3)-bbbbb -D-glucan was
initially associated with the cellular com partm ent, and
this value decreased further during the 2-h period fol-
lowing adm inistration (P = 0.0001). Over 97%  of 
125I-
(1®®®®® 3)-bbbbb -D-glucan was associated with cell-free plasm a,
and the m ajority in plasm a appeared to be present in
the unbound form  (not associated with lipoproteins or
plasm a proteins). The liver contained more than 80%
of the 
125I-(1®®®®® 3)-bbbbb -D-glucan detected in the six major
organs analyzed.
K ey w o rd s:   (1® 3 )-b -D-g lucan,  p har m acok inetics,
biological effects
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Introduction
Invasive  deep  m ycoses  are  becoming  increasingly
com mon.  Recently,  a  test  to  determine  the  plasm a
concentration of (1® 3)-b -D-glucan, a ubiquitous con-
stituent of fungi, has been developed in order to al-
low an early diagnosis of deep mycosis and fungal
sepsis [1,2].
Knowledge of the biological activities of (1® 3)-
b -D-glucan is expanding, with the recent recognition
that  this  substance  can  stimulate  the  production  of
platelet-activating  factor,  tumor  necrosis  factor,  in-
terleukin-1 (IL-1), IL-1 receptor antagonist and sev-
eral prostaglandins in some experimental m odels [3±
5]. The (1® 3)-b -D-glucan receptor has been identi-
fied in monocytes [6] and also has been found in sev-
eral other inflammatory cells. Therefore, in the case
of  deep  mycosis  or  fungemia,  fungi  could  activate
cells  through  the  (1® 3)-b -D-glucan  receptor,  and
cause inflammatory responses. Also of interest is the
metabolic fate of (1® 3)-b -D-glucan in vivo. In endo-
toxemia, the majority of lipopolysaccharide is found
in cell-free plasm a, especially in the high-density li-
poprotein (HDL) fraction.  This lipopolysaccharide±
HDL  com plex  is  thought  to  be  less  bioactive  than
free lipopolysaccharide [7]. However, no information
is  available  about  potential  associations  betw een
(1® 3)-b -D-glucan and plasma proteins. Therefore we
evaluated the pharmacokinetics of intravenously ad-
ministered (1® 3)-b -D-glucan and its distribution be-
tween  blood  cells  and  plasma  proteins,  using  radi-
olabeled  (1® 3)-b -D-glucan  purified  from  Candida
albicans.
Methods
(1® 3)-b -D-glucan
(1® 3)-b -D-glucan was purified from Candida albi-
cans [Institute for Fermentation (IFO) 1385, Ameri-
can Type Culture Collection (ATCC) 18804]. The av-
erage m olecular weight of glucan dissolved in NaOH
was 92 000. Purified glucan was dissolved with 0.09 N
NaOH,  and radio-iodination with 
125I was then per-
formed using the method initially described for radio-
labeling  endotoxin  [8].  T he specific  activity  w as
2.50 m Ci/m g.  The  purified  (1® 3)-b -D-glucan  con-
tained less than 20 pg endotoxin/mg glucan, as de-
term ined  by  the  endotoxin-specific  chrom ogenic
lim ulus  test  (E ndospecy,  Seikagaku  Corporation,
Tokyo,  Japan).  Contamination  by endotoxin during
radiolabeling was minim al (1.2 ng endotoxin/m g 
125I-
(1® 3)-b -D-glucan).
Experimental protocol
New Zealand W hite female rabbits were divided into
three  groups:  (1)  control  (distilled  w ater  group)280         Mediators of Inflammation ￿ Vol 6 ￿ 1997
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(n = 2),  (2) low-dose (1® 3)-b -D-glucan (n = 3) and
(3) high-dose (1® 3)-b -D-glucan (n = 3). A bolus in-
travenous injection of 9.3 m g/kg 
125I-(1® 3)-b -D-glu-
can (specific activity 2.50 m Ci/m g; low-dose group)
or a mixture of 12.1 m g/kg 
125I-(1® 3)-b -D-glucan plus
209.9 m g/kg non-radiolabeled (1® 3)-b -D-glucan (to-
tal 222 m g/kg, specific activity 0.14 m Ci/m g; high-dose
group)  was  administered  into  a  m arginal  ear  vein.
Blood samples for measurement of the intravascular
clearance of (1® 3)-b -D-glucan were drawn from  the
opposite  ear  vein  using  a  capillary  tube  (70 m l),  at
0.25, 0.5, 1, 2, 3, 5, 10, 15, 20, 25, 30, 60 and 90 min,
and 2, 3, 6, 12 and 24 h. Radioactivity of the whole
blood samples was measured with a g -counter (mod-
el 500; Packard Instrument Co., Downers Grove, Il-
linois, USA).
Blood samples (3 ml) for blood cell counts and for
the fractionation of cellular and plasma components
were also drawn at 1, 5,  10 and 30 min, and 2 and
24 h.  Blood samples  (2 ml)  for  the Fungitec  G test
(Seikagaku Corporation) were obtained at 1, 2, 5, 10,
20, 30, 60 and 90 m in, and 2, 3, 6, 12 and 24 h. Dur-
ing  the  24-h  period  of  observation,  the  rabbits  re-
mained well.
To study the distribution of 
125I-b -glucan in whole
blood  in vitro, blood samples (3 ml) were collected
before  adm inistration  of  (1® 3)-b -D-glucan.  These
samples were then incubated with 200 m l radiolabeled
(1® 3)-b -D-glucan (85.4 ng) for 20 min at room tem-
perature, before fractionation.
Analysis of 
125I-(1® 3)-b -D-glucan clearance in whole
blood
To determine the 
125I-(1® 3)-b -D-glucan clearance in
whole  blood,  the  tim e  0  value  (counts/min  per  m l
whole blood) was calculated using the form ula: total
counts/min of injected 
125I-(1® 3)-b -D-glucan/estimat-
ed blood volum e (70 ml/kg ´ rabbit weight in kilo-
grams).  The intravascular  half-life (T1/2)  was  deter-
mined from the clearance curve. The area under the
concentration±time curve (AUC in ng/ml ´ min) was
calculated  by  trapezoid  integration:  S (1/2(t n+1 ±
tn)(C n+1 + C n), where  t is time in minutes,  n is time
point of blood sampling and C is concentration. To-
tal body clearance was then calculated as: total dose
of injected 
125I-(1® 3)-b -D-glucan/AUC (in ml/min).
Determination of (1® 3)-b -D-glucan concentration in
serum using the G test
The  (1® 3)-b -D-glucan  concentration  in  serum  was
determ ined with the G test [9]. (1® 3)-b -D-glucan ex-
tracted from the mushroom Poria cocos was used as
a standard. Since the factor G-activating activity of
(1® 3)-b -D-glucan  purified  from  Candida  albicans
was 1:200 on a weight basis compared to  Poria co-
cos, the concentration of (1® 3)-b -D-glucan, as meas-
ured by the G test, was multiplied by 200 to obtain
the  corrected  concentrations  for  Candida  albicans.
Serum samples outside the range of the standard curve
were measured after dilution with distilled water. The
limit of detection in water (or 0.9%  NaCl) of Poria
cocos was 1.0 pg/ml.
Fractionation of whole blood and separation of
lipoproteins from cell-free plasma
Fractionations were performed at room temperature,
as described previously [10]. Platelets, mononuclear
cells,  polymorphonuclear  leukocytes,  erythrocytes
and cell-free plasma were collected.  Cell-free plas-
ma was subjected to sequential ultracentrifugation at
8Ê C at plasm a density (1.006 g/m l) for 18 h, at a den-
sity of 1.063 g/ml with KBr for 18 h, and finally at a
density  of  1.21 g/ml  with  KBr  for  40 h  in  order  to
isolate very-low-density lipoproteins (VLDL),  low-
density  lipoproteins  (LDL)  and  HDL, respectively,
and  to  isolate  lipoprotein-deficient  plasma  (density
>1.21  g/m l).  Following  in  vitro  incubation  of 
125I-
(1® 3)- b -D-glucan with normal saline (0.9%  NaCl),
these steps were also performed to determ ine the den-
sity distribution pattern of (1® 3)-b -D-glucan.
Separation of lipoproteins by precipitation
Separation of VLDL and LDL from serum was per-
formed using the m ethod provided by Sigm a Diag-
nostic Kit  352-4 (Sigma Chemicals, St Louis,  Mis-
souri,  USA).  T he  separation  of  all  lipoproteins
(VLDL, LDL and HDL) from serum was performed
using dextran and M gCl2.
Separation of serum proteins by gel-permeation
chromatography
Solutions of 
125I-(1® 3)- b -D-glucan in water (85.4 ng
in 200  m l) and  in  rabbit  serum  (after incubation  of
125I-(1® 3)- b -D-glucan with 1 ml rabbit serum for 30
min  at  37Ê C  in  vitro)  were  chrom atographed  on  a
Superose 12 column, using a fast protein liquid chro-
matography system (Pharm acia LKB Biotech, Upp-
sala, Sweden). Proteins were m onitored at A 280, and
125I-(1® 3)- b -D-glucan was monitored by determina-
tion of 
125I in counts/m in.
Distribution of 
125I-(1® 3)-b -D-glucan in tissues
The  distribution  of 
125I-(1® 3)- b -D-glucan  in  liver,
spleen, kidney,  adrenal, lung and heart  was studied
in anim als killed 24 h after the injection.
Data analysis
A two-tailed t-test and analysis of variance with re-
peated measures were performed. P < 0.05 was con-
sidered significant.Pharmacokinetics, biological effects and distribution
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Table 1. Pharmacokinetics after an intravenous injection of (1 ® 3)-
b -D-glucan
AUC Total body T1/2
Dose (m g/kg) (ng/ml´ min) clearance (ml/min)  (min)
Low dose (9.3) 11 811 ± 2 718 1.12 ± 0.30 1.8
High dose (222) 460 451 ± 75 982 1.17 ± 0.16 1.4
Values are means ± SD. AUC, area under the concentration–time curve;
T1/2, half-life.
FIG. 1. Intravascular clearance (means ± SEM) of (a) 
125I-(1® 3)-
b -D-glucan and (b) total (1® 3)-b -D-glucan determined by the G
test, after intravenous administration in rabbits. Open circles, low-
dose group [9.3 m g/kg of 
125I-(1® 3)-b -D-glucan, n = 3]; closed cir-
cles, high-dose group [12.1 m g/kg of 
125I-(1® 3)-b -D-glucan plus
209.9 m g/kg of non-radiolabeled (1® 3)-b -D-glucan, n = 3].
Results
Intravascular clearance of 
125I-(1® 3)-b -D-glucan
Fig. 1a shows the pattern of intravascular  clearance
of 
125I-(1® 3)-b -D-glucan during the initial 3 h.  The
intravascular half-life (T1/2) of 
125I-(1® 3)-b -D-glucan
in  the low-dose  group was  1.8 min, and that in  the
high-dose group was 1.4 min (not significantly dif-
ferent).  The  AUC and  total body  clearance in  each
group are shown in Table 1.
Rapid clearance of glucan biological activity was
demonstrated by the G test for both low- and high-
dose groups, with T 1/2 values of 4.1 and 2.1 min, re-
spectively  (Fig.  1b).  There  was  a  good  correlation
betw een the isotopic and the biologic methods.
Blood cell levels
The effects of (1® 3)-b -D-glucan on blood cell levels
were minimal over 24 h (data not shown).
Distribution of 
125I-(1® 3)-b -D-glucan in blood
Almost all 
125I-(1® 3)-b -D-glucan was associated with
the cell-free plasma in both groups (Table 2).  Less
than  3%   was  associated  with  the  cellular  compart-
ment, and this value decreased further during the in-
itial 2-h period after 
125I-(1® 3)-b -D-glucan adminis-
tration (P = 0.0001).
Distribution of 
125I-(1® 3)-b -D-glucan in the cellular
compartment
M ost 
125I-(1® 3)-b -D-glucan in blood cells was asso-
ciated with platelets 1 min after the injection. After
2 h, the percentage associated with platelets decreased
(P = 0.0001).  Concomitantly, the proportion of 
125I-
(1® 3)-b -D-glucan  associated  w ith  polym orpho-
nu clear  neutrophils  and  erythro cytes  increased
(P = 0.0008 and P = 0.0001, respectively). However,
the absolute quantity of 
125I-(1® 3)-b -D-glucan asso-
ciated with both fractions decreased because the per-
centage in the cellular compartment decreased from
2.5±3.0 to 0.4%  during this period (Table 3).
Distribution of 
125I-(1® 3)-b -D-glucan among the
components of cell-free plasma
M ore  than  60%  of  the injected 
125I-(1® 3)-b -D-glu-
can was recovered from the lipoprotein-free fraction
Table 2. Distribution of 
125I-(1® 3)-b -D-glucan (counts/min) in whole blood
% Plasma % Cells
Low dose High dose Low dose High dose
Time after injection
1 min 97.0 ± 0.3 97.5 ± 0.8 3.0 ± 0.3 2.5 ± 0.8
5 min 97.7 ± 1.5 98.6 ± 0.3 2.3 ± 1.5 1.4 ± 0.3
10 min 98.8 ± 0.5 99.1 ± 0.3 1.2 ± 0.5 0.9 ± 0.2
30 min 99.3 ± 0.2 99.4 ± 0.2 0.7 ± 0.2 0.6 ± 0.1
120 min 99.6 ± 0.2 99.6 ± 0.2 0.4 ± 0.2 0.4 ± 0.2
In vitro incubation 99.1 ± 0.3 0.9 ± 0.3
Values are means ± SD.282         Mediators of Inflammation ￿ Vol 6 ￿ 1997
M. Yosihida et al.
Table 3. Distribution of 
125I-(1® 3)-b -D-glucan (counts/min) in blood cellular compartments
% Platelets %MNC %PMN % Erythrocytes
Low dose High dose Low dose High dose Low dose High dose Low dose High dose
Time after injection
1 min 51.9 ± 8.4  70.4 ± 6.1 33.4 ± 8.9  14.6 ±10.6  5.2 ± 2.4  6.9 ± 5.4  9.5 ± 3.6  8.1 ± 2.3
5 min  53.4 ± 19.0   61.2 ± 11.6 23.4 ± 7.8  11.6 ± 11.8  9.3 ± 5.4 11.5 ± 6.8 13.9 ± 7.2 15.8 ± 3.1
10 min  48.2 ± 32.0  36.7 ± 4.9  17.1 ± 17.1  16.3 ± 14.4 10.2 ± 4.5  21.0 ± 15.9   24.4 ± 10.7 26.0 ± 3.6
30 min 25.5 ± 7.6  22.1 ± 6.2  22.3 ±23.3 23.8 ± 8.7 12.5 ± 3.8 20.0 ± 2.4    39.7 ± 12.5 34.0 ± 3.6
120 min  17.9 ± 19.4    5.1 ± 8.8   0 ± 0  19.1 ± 20.5  30.7 ± 11.8  38.8 ± 23.8   51.4 ± 20.0 36.9 ± 9.8
In vitro incubation 44.2 ± 10.5 17.3 ± 11.5 14.1 ± 7.9 24.4 ± 11.9
100% represents total counts/min of 
125I-(1® 3)-b -D-glucan in the cellular compartment; MNC, mononuclear cells; PMN, polymorphonuclear neutrophils.
Table 4. 
125I-(1® 3)-b -D-glucan distribution (% total counts/min) in normal saline and cell-free plasma
Density <1.006 g/ml Density 1.006–1.063 g/ml Density 1.063–1.21 g/ml Density >1.21 g/ml
Sample Low dose High dose Low dose High dose Low dose High dose Low dose High dose
Normal saline 13.3 ± 0.4 7.7 ± 1.1 14.7 ± 3.7 64.5 ± 4.6
Plasma
In vitro incubation  9.5 ± 0.7 7.2 ± 0.5 17.7 ± 0.9 65.6 ± 2.1
Time after injection
1min  8.4 ± 1.7  9.8 ± 1.0  6.8 ± 1.7  7.4 ± 0.9 16.3 ± 2.5 19.1 ± 2.1 68.5 ± 5.0 63.7 ± 3.6
5 min 10.7 ± 1.4 11.8 ± 0.5  8.1 ± 0.8  8.7 ± 0.6 20.2 ± 1.3 22.1 ± 0.9 60.9 ± 3.5 57.5 ± 1.5
10 min 12.0 ± 0.9 12.4 ± 0.5  9.2 ± 0.6  9.4 ± 0.4 21.3 ± 0.3 23.0 ± 1.0 57.5 ± 1.6 55.3 ± 1.7
30 min 12.8 ± 0.2 13.6 ± 0.5 10.0 ± 0.2 10.2 ± 0.4 23.4 ± 0.4 24.4 ± 0.1 53.7 ± 0.5 51.8 ± 0.8
120 min 14.2 ± 0.5 14.9 ± 0.4 11.3 ± 0.1 11.8 ± 0.5 25.0 ± 1.1 25.0 ± 0.3 49.5 ± 0.8 48.3 ± 1.0
(density  >1.21 g/ml).  Two hours  after  the  adm inis-
tration of 
125I-(1® 3)-b -D-glucan,  there was  a  small
but  significant  increase  in  the  proportion  of 
125I-
(1® 3)-b -D-glucan  associated  with  the  three  lower-
density fractions (P = 0.0001 for each fraction), and
a significant decrease in the fraction with a density
of >1.21 g/ml (P = 0.0001; Table 4).
The KBr density centrifugation results suggest that
(1® 3)-b -D-glucan in blood had only minim al asso-
ciation  with  lipoproteins.  To  examine  this by  inde-
pendent techniques, solutions of 
125I-(1® 3)-b -D-glu-
can in normal saline and in serum sam ples obtained
3, 10 and 120 min after administration of 
125I-(1® 3)-
b -D-glucan were subjected to conditions known to pre-
cipitate  lipoproteins  (one  for  the  precipitation  of
VLDL and LDL only, and the other for VLDL, LDL
and  HDL).  With  precipitation  by  the  form er  tech-
nique,  only 4.1%  of 
125I-(1® 3)-b -D-glucan  was  re-
covered in the VLDL + LDL precipitates from serum,
and this was no different from the proportion precip-
itated from  norm al saline (3.9% ).  The second tech-
nique,  for  precipitation  of  all  lipoproteins,  precipi-
tated 10%  of the 
125I-(1® 3)-b -D-glucan in serum com-
pared to 1.9%  from  a saline solution of 
125I-(1® 3)-b -
D-glucan, suggesting some association with HDL.
In the gel-permeation chrom atographic analysis of
rabbit  serum,  all  lipoproteins  appeared  in  the  void
volume, and therefore were distinguishable from other
plasm a proteins. The patterns of distribution of radio-
activity in the solutions of 
125I-(1® 3)-b -D-glucan in
rabbit  serum  or  in  water  were  alm ost  identical;  47
and 51%  were recovered in the void volume fractions,
respectively, and the rem ainder was recovered in the
included volum e (Fig. 2).
Distribution of 
125I-(1® 3)-b -D-glucan in tissues
The liver contained more than 80%  of the 
125I-(1® 3)-
b -D-glucan  distributed  in the six major  organs,  fol-
FIG. 2. Separation of rabbit serum proteins by gel-permeation chro-
matography. Solutions of 
125I-(1® 3)-b -D-glucan in water or rabbit
serum were chromatographed on a Superose 12 column. Pro-
teins were monitored at A280 and (1® 3)-b -D-glucan was monitored
by determination of 
125I in counts/min. The void volume (V0) and
the molecular weight standards are indicated. VLDL, very-low-
density lipoprotein; LDL, low-density lipoprotein; HDL, high-den-
sity lipoprotein.Pharmacokinetics, biological effects and distribution
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the remainder eluted broadly within the included vol-
ume (<2 ´ 10
6 daltons) without any alteration in size
distribution,  suggesting  that  binding  of 
125I-(1® 3)-
b -D-glucan to plasma proteins was unlikely. In addi-
tion, based on the results of both lipoprotein precipi-
tation methods, only a minor proportion of 
125I-(1® 3)-
b -D-glucan apparently bound to HDL, and binding to
VLDL and LDL was not demonstrated.
In conclusion, soluble (1® 3)-b -D-glucan purified
from  Candida albicans showed a rapid clearance rate
and failed to alter blood cell counts. M ost (1 ® 3)-b -
D-glucan seems to occur in the unbound form in plas-
ma. It is unlikely that circulating (1® 3)-b -D-glucan
is the m olecule responsible for the pathophysiologic
changes observed  in  patients with  deep m ycosis or
fungem ia.
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lowed by the kidney (approxim ately 10% ).  In both
dose groups, the spleen, liver and kidney contained
high concentrations of 
125I-(1® 3)-b -D-glucan.
Discussion
On the basis of our clinical observations [1,2,11], the
elevation of plasma (1® 3)-b -D-glucan levels in pa-
tients with fungemia is m ore common and more pro-
longed than elevated endotoxin levels in Gram-nega-
tive  bacterem ia  [12].  However,  the  intravascular
clearance of 
125I-b -D-glucan was unexpectedly rapid.
This suggests that a continuous release of  b -glucan
would be  necessary to maintain high plasm a  levels
in patients with fungemia. Despite the reported bio-
logical activities of b -glucan, injected soluble (1® 3)-
b -D-glucan did not produce significant alterations in
blood  cell  levels.  M oreover,  the  adm inistration  of
(1® 3)-b -D-glucan did not  produce a significant al-
teration  in  the  production  of  tumor  necrosis  factor
(data not shown).
In the present study, alm ost all injected (1® 3)-b -
D-glucan was found in cell-free plasma. After sequen-
tial  ultracentrifugation,  m ore  than  60%   of  injected
(1® 3)-b -D-glucan was recovered from the lipopro-
tein-free  fraction (density  >1.21 g/ml).  The  VLDL,
LDL and HDL fractions were each associated with
approximately 10%   of  the injected  (1® 3)-b -D-glu-
can in the early time-point sam ples. However, a sim -
ilar  density  distribution  pattern  was  obtained  when
the (1® 3)-b -D-glucan had been incubated with nor-
mal  saline  in  vitro .  These results  indicated  that the
distribution  of  (1® 3)-b -D-glucan  found  in  plasma
fractions  does  not represent a  true  binding  to  lipo-
proteins or other plasma proteins, but rather is prob-
ably a reflection of the heterogeneity of our prepara-
tion of (1® 3)-b -D-glucan, which contained compo-
nents with different densities. Our data from gel-per-
meation chromatography support this interpretation.
Approximately 50%  of the 
125I-(1® 3)-b -D-glucan in
either water or serum was recovered from the void
volume fraction (which contains all lipoproteins) and